1	Three families of CD4-induced antibodies are associated with the capacity of plasma from
2	people living with HIV to mediate ADCC in presence of CD4-mimetics
3	
4	Alexandra Tauzin <sup>1,2</sup> , Lorie Marchitto <sup>1,2</sup> , Étienne Bélanger <sup>1,2</sup> , Mehdi Benlarbi <sup>1,2</sup> , Guillaume
5	Beaudoin-Bussières <sup>1,2</sup> , Jérémie Prévost <sup>1,2</sup> , Derek Yang <sup>3</sup> , Ta-Jung Chiu <sup>3</sup> , Hung-Ching Chen <sup>3</sup> ,
6	Catherine Bourassa <sup>1</sup> , Halima Medjahed <sup>1</sup> , Marek K Korzeniowski <sup>4</sup> , Suneetha Gottumukkala <sup>4</sup> ,
7	William D. Tolbert <sup>4</sup> , Jonathan Richard <sup>1,2</sup> , Amos B Smith III <sup>3</sup> , Marzena Pazgier <sup>4</sup> , Andrés Finzi <sup>1,2</sup>
8	
9	<sup>1</sup> Centre de Recherche du CHUM, Montreal, QC, Canada
10	<sup>2</sup> Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal,
11	QC, Canada
12	<sup>3</sup> Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia,
13	PA, USA
14	<sup>4</sup> Infectious Diseases Division, Department of Medicine, Uniformed Services University of the
15	Health Sciences, Bethesda, MD, USA
16	
17	Corresponding author: Andrés Finzi, andres.finzi@umontreal.ca
18	
19	Running title: PLWH plasma heterogeneity in response to CD4mc
20	
21	Abstract word count: 132
22	Text word count: 5539
23	
24	

#### 25 ABSTRACT

26

CD4-mimetics (CD4mcs) are small molecule compounds that mimic the interaction of the CD4 27 28 receptor with HIV-1 envelope glycoproteins (Env). Env from primary viruses normally samples a 29 "closed" conformation which occludes epitopes recognized by CD4-induced (CD4i) non-30 neutralizing antibodies (nnAbs). CD4mcs induce conformational changes on Env resulting in the 31 exposure of these otherwise inaccessible epitopes. Here we evaluated the capacity of plasma from 32 a cohort of 50 people living with HIV to recognize HIV-1-infected cells and eliminate them by 33 antibody-dependent cellular cytotoxicity (ADCC) in the presence of a potent indoline CD4mc. We 34 observed a marked heterogeneity among plasma samples. By measuring the levels of different families of CD4i Abs, we found that the levels of anti-cluster A, anti-coreceptor binding site and 35 36 anti-gp41 cluster I antibodies are responsible for plasma-mediated ADCC in presence of CD4mc. 37

38

#### **39 IMPORTANCE**

40 There are several reasons that make it difficult to target the HIV reservoir. One of them, is the 41 capacity of infected cells to prevent the recognition of HIV-1 envelope glycoproteins (Env) by 42 commonly-elicited antibodies in people living with HIV. Small CD4-mimetic compounds expose 43 otherwise occluded Env epitopes, thus enabling their recognition by non-neutralizing antibodies. 44 A better understanding of the contribution of these antibodies to eliminate infected cells in presence 45 of CD4mc could lead to the development of therapeutic cure strategies.

46

47

#### 48 INTRODUCTION

49

50 The human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein is a trimer of gp120/gp41 heterodimers non-covalently associated and highly glycosylated (1, 2). Env is the sole 51 52 viral protein expressed at the surface of virions and infected cells and mediates viral entry into 53 target cells. During the entry process, Env undergoes different conformational changes 54 transitioning from its native unliganded "closed" conformation (State-1) (3, 4) to a "partially open" conformation (State-2) upon interaction with a single CD4 receptor to an "open" conformation 55 56 (State-3) after engagement of its three gp120 subunits to CD4 (5, 6). After interaction with the CCR5 or CXCR4 coreceptor (7, 8) Env releases its gp41 fusion peptide which inserts into the cell 57 membrane, thereby triggering fusion between the virion and the target cell (7). 58

59

After infection, the HIV-1 accessory proteins Nef and Vpu prevent CD4 expression at the surface 60 61 of infected cells via different mechanisms. Nef acts on CD4 expressed at the surface of infected cells while Vpu acts on newly-synthetized CD4 in the endoplasmic reticulum (ER), leading to 62 lysosomal degradation or ER-associated protein degradation (ERAD), respectively (9, 10). Thus, 63 64 Env expressed at the surface of infected cells are free of CD4 and therefore samples a "closed" 65 conformation, preventing recognition of the infected cells by commonly elicited CD4-induced 66 (CD4i) non-neutralizing antibodies (nnAbs). These antibodies were shown to eliminate infected 67 cells by antibody-dependent cellular cytotoxicity (ADCC) when Env samples the "open" 68 conformation (11, 12).

69

70 Based on these observations, small CD4-mimetic compounds (CD4mcs) have been used to force 71 Env to adopt more "open" conformations, successfully sensitizing HIV-1-infected cells to ADCC 72 mediated by CD4i Abs and plasma from PLWH (13-17). CD4mcs are HIV-1 entry inhibitors that bind the Phe43 cavity, a highly conserved region of the gp120 (18–21). Binding of CD4mcs to the 73 Phe43 cavity induces conformational changes that allow the exposition of vulnerable CD4i Env 74 75 epitopes (14, 16, 17, 22–25). To our knowledge, the recently-described indoline CD4mc CJF-III-76 288 is the most potent CD4mc to sensitize HIV-1-infected cells to ADCC mediated by PLWH 77 plasma (23). We previously reported the role of two families of nnAbs, recognizing the coreceptor binding site (anti-CoRBS Abs) and the cluster A (anti-cluster A Abs) as being important for PLWH 78 plasma to mediate ADCC in presence of CD4mc (14, 17, 24-26). This combination of nnAbs 79 80 together with the indane BNM-III-170 CD4mc was shown to stabilize a nnAb-vulnerable Env 81 conformation, State-2A (17). Administration of this combination to humanized mice (hu-mice)

resulted in a significant decrease in the size of the viral reservoir (25). In addition to these two CD4i
Abs, we recently observed that CD4i nnAbs recognizing the cluster I region of the gp41 (anti-gp41
cluster I Abs), can mediate potent ADCC and reduce HIV-1 replication in hu-mice when combined
with CD4mc (16).

86

In this study, we analyzed the capacity of plasma from a cross-sectional cohort of PLWH to recognize HIV-1-infected cells and mediate ADCC in the presence of a CD4mc. We observed a marked heterogeneity which was associated to the levels of anti-cluster A, anti-coreceptor binding site and anti-gp41 cluster I antibodies.

- 91
- 92

93 **RESULTS** 

94

## 95 CJF-III-288 enhances the capacity of plasma from PLWH to recognize Env at the surface of 96 infected cells and to mediate ADCC activity.

97

98 We previously demonstrated that CD4mc sensitizes HIV-1-infected cells to ADCC mediated by 99 plasma from PLWH (13, 23). However, whether the time post-infection or ART treatment could 100 impact the capacity of these plasma to mediate ADCC in the presence of CD4mc remain to be 101 determined. We therefore evaluated the capacity of plasma from a cross-sectional cohort of PLWH 102 to recognize and eliminate HIV-1-infected cells by ADCC. This cohort of PLWH was separated 103 into five different groups: four groups were composed of donors who were not under antiretroviral therapy (ART) and collected at different time post-infection: 0-100 days post-infection; 101-180 104 days post-infection; 181-365 days post-infection and 2-5 years post-infection. The last group was 105 106 composed of donors under ART collected 2-5 years post-infection. Basic demographic data of the cohort is summarized in Table 1. Briefly, we infected primary CD4+ T cells with the infectious 107 molecular clone (IMC) HIV-1-JRFL and measured the ability of these plasmas to recognize Env 108 expressed at the surface of productively HIV-1-infected cells (CD4<sup>low</sup> p24+) by flow cytometry. 109 110 Plasma samples weakly recognized infected cells in the presence of the vehicle (DMSO, Figure 111 1A). However, upon addition of the indoline CD4mc CJF-III-288, recognition by all plasma was significantly enhanced. This enhanced recognition translated into a marked increase in ADCC 112 activity (Figure 1B), as measured with a previously described FACS-based ADCC assay (11, 13, 113 114 27). As expected, recognition of infected cells by plasma samples was significantly associated with

their ADCC activity (Figure 1C). Interestingly, we observed a marked heterogeneity in the capacity

116 of tested PLWH plasma to recognize and mediate ADCC in the presence of CD4mc.

117 When comparing the responses within plasmas from the different groups of donors, we observed

that CJF-III-288 strongly increased Env recognition and ADCC activity compared to DMSO in all

119 groups (Figure 1D-E). We also observed that the capacity of plasma to recognize Env and to

120 mediate ADCC in presence of CJF-III-288 increased with time after infection in untreated donors.

- 121
- 122

### 123 Three families of CD4i nnAbs contribute to PLWH plasma ability to mediate ADCC in 124 presence of CD4mc.

125

126 We hypothesized that the differential composition in CD4i nnAbs could potentially explain the observed heterogenicity in the capacity of PLWH plasma to mediate ADCC in the presence of CJF-127 128 III-288. Previously, we reported that the combination of anti-CoRBS and anti-cluster A Abs with 129 the indane CD4mc BNM-III-170 can mediate potent ADCC against HIV-1-infected cells both in 130 vitro and in vivo (14, 17, 24–26). More recently, we reported that anti-gp41 cluster I Abs could also 131 mediate ADCC in the presence of CD4mc (16). To better understand the contribution of these 132 families of CD4i nnAbs to ADCC, we measured their levels respective by indirect ELISA, as 133 described in the material and methods section. All PLWH plasmas had different but detectable anti-134 cluster A and anti-gp41 cluster I Abs in their plasma (Figure 2A). In contrast, we were unable to 135 detect anti-CoRBS Abs in some donors (Figure 2A). When stratified by groups, only one donor of 136 the 0-100 days post-infection group had detectable anti-CoRBS Abs, and the levels of anti-cluster A Abs were weak compared to the other groups (Figure 2B). In contrast, anti-gp41 cluster I Abs 137 were readily detected in these early samples. The levels of the three families of Abs progressively 138 139 increased over time and, while the level of anti-gp41 Abs always remained higher than the two 140 other families of Abs, we did not see significant differences between the levels of anti-cluster A 141 and anti-CoRBS Abs after 181 days post-infection. Of note, the capacity of these plasma samples to mediate ADCC correlated with the levels of each of these three families of antibodies in the 142 143 presence, but not in its absence of CD4mc (Figure 2C-H).

144

145 To evaluate the contribution of anti-CoRBS, anti-cluster A and anti-gp41 cluster I Abs to plasma-

146 mediated ADCC in the presence of CJF-III-288, we performed a Fab fragment competition assay.

147 Briefly, infected cells were preincubated with CJF-III-288 in presence of anti-CoRBS, anti-cluster

148 A or anti-gp41 cluster I Fab fragments, or a combination of the three Fab fragments. In this

149 experimental setting, Fab fragments bind to their respective epitopes exposed by the CD4mc, and 150 therefore prevent the binding of antibodies from the same family present in plasma from PLWH. 151 This inhibits any ADCC activity mediated by Abs recognizing overlapping epitopes. Preincubation with anti-CoRBS Fab fragments but not anti-cluster A or anti-gp41 cluster I Fab fragments 152 153 decreased the capacity of PLWH plasma to recognize Env in presence of the CD4mc (Figure 3A). Despite their lack of blocking activity individually, anti-cluster A and anti-gp41 cluster I Fab 154 155 fragments decreased PLWH plasma binding to infected cells when combined with anti-CoRBS Fab fragments, in agreement with a sequential opening of the trimer by CD4mc in combination with 156 157 CD4i Abs (14). Interestingly, incubation with each of the three Fab fragments decreased ADCC, 158 albeit this difference was significant only in presence of anti-CoRBS Fab fragments (Figure 3B). Combination of the 3 Fab fragments decreased ADCC levels to those observed in the absence of 159 160 CD4mc, further demonstrating the importance of these three families of antibodies for the elimination of infected cells by ADCC. 161 162

163

## 164 Anti-CoRBS, cluster A and gp41-cluster I antibodies contribute to plasma-mediated 165 elimination of autologous primary CD4+ T cells by ADCC.

166

167 To extend our analysis to primary clinical samples, we expanded CD4+ T cells from different ART-168 treated PLWH (Table 2) and measured the capacity of each donor's plasma to eliminate autologous 169 endogenously-infected CD4+ T cells by ADCC in presence of the CJF-III-288 CD4mc. Briefly, 170 CD4+ T cells were isolated from PLWH, activated ex vivo with PHA-L/IL-2 and viral replication was followed by intracellular p24 staining (Figure 4A). When we detected at least 7% of p24+ cells 171 in the culture, we evaluated the capacity of autologous plasma to recognize and eliminate infected 172 173 cells by ADCC in presence or absence of CJF-III-288 (Figure 4B-C). In agreement with our in vitro 174 experiments, CD4mc addition significantly increased the recognition of infected cells (Figure 4B), 175 and sensitized them to ADCC (Figure 4C). We then performed Fab fragment competition 176 experiments to evaluate the contribution of anti-CoRBS, anti-cluster A and anti-gp41 cluster I Abs 177 from autologous plasma to mediate ADCC. Preincubation with the combination of the three Fab 178 fragments led to a reduction in ADCC activity, albeit to different extents depending on the donor. 179

180

#### 181 **DISCUSSION**

182

183 Env is the only viral antigen expressed at the surface of virions and infected cells, making it the main target of the humoral response (28). However, while antibodies are elicited against Env after 184 185 HIV-1 infection, only a rare subset of these antibodies - broadly neutralizing antibodies (bNAbs) effectively recognize Env in its native, "closed" conformation (3, 6). The majority of antibodies 186 187 commonly induced in PLWH are non-neutralizing and typically recognize regions of Env that are occluded within the unliganded Env trimer (29). Interestingly, epitopes for some nnAbs map to the 188 189 most conserved regions of Env that are hidden in the unliganded "closed" conformation (18, 30-34). A strategy to harness the inherent potential of these antibodies is to "open-up" Env with 190 CD4mc, thus exposing otherwise hidden epitopes (13, 14, 16, 17). We previously showed that 191 addition of CD4mc sensitize primary infected CD4+ T cells to ADCC mediated by autologous 192 plasma (13). We also showed that CD4mc acts in coordination with anti-CoRBS Abs to "open" 193 194 Env leading to the exposure of cluster A epitope (14, 24). Anti-cluster A Abs binding stabilizes an asymmetric Env conformation (State-2A) leading to the elimination of infected cells by ADCC (14, 195 196 17, 24, 35). Administration of a cocktail of CD4mc with anti-CoRBS/anti-cluster A Abs or with 197 plasma from PLWH results in the significant reduction of the viral reservoir accompanied by a 198 significant delay in viral rebound in hu-mice (25).

199

200 In this study, we report that anti-CoRBS Abs, anti-cluster A Abs and a third family of nnAbs 201 (against the gp41 cluster I region), play significant roles in the capacity of any given PLWH plasma to mediate ADCC in the presence of CD4mc. As shown in Figure 5, each of these three families of 202 203 nnAbs targets highly conserved and non-overlapping regions of Env. Anti-CoRBS Abs interact 204 with regions involved in coreceptor binding (mapping to the outer domain of gp120 at the base of 205 V3 loop), which are necessary for the virus to enter host cells. Since they are involved in coreceptor 206 binding, residues forming the CoRBS are invariable among HIV-1 clades (Figure 5). The cluster A 207 region maps to the gp41 interactive face of gp120, within the topological layers of the gp120 inner 208 domain in the C1-C2 regions, contributing to the structural stabilization of the trimer (33, 36, 37). 209 The cluster A region consists of two non-overlapping sub specificities: A32- and C11-epitope regions (both mapped on Figure 5). The A32 region maps exclusively within the inner domain of 210 gp120 and includes residues within the inner domain mobile layer 1 (centered around CD4 induced 211  $\alpha$ 0 helix) of the constant region 1 (C1) region and layer 2 (centered around the  $\alpha$ 1 helix) of the C2 212 213 region. Residues of the gp120 outer domain and the N- and C-termini of gp120 are not part of the 214 A32 epitope. In contrast, the C11 epitope involves residues of the eight-stranded  $\beta$ -sandwich region

215 of the gp120 inner domain that is formed by docking the gp120 N-terminus to the 7-stranded  $\beta$ -216 sandwich. The gp120 C1, C2 and eight-stranded  $\beta$ -sandwich regions where cluster A epitopes are 217 located are highly conserved across different HIV-1 isolates (Figure 5). During the transition to the CD4-induced conformation, this region undergoes a significant structural rearrangement (18, 30, 218 219 32, 33, 38, 39). Finally, anti-gp41 cluster I antibodies recognize a linear epitope in the disulfide loop region (DLR, linking HR1 and HR2 helices) of the principal immunodominant domain (PID) 220 221 of gp41 (34) (Figure 5). The gp41 sequence recognized by Cluster I Abs 246D and F240 is highly conserved among HIV-1 isolates. F240 has been shown to be broadly cross-reactive and capable 222 223 of reacting with primary isolates from all clades of HIV-1 (16, 40, 41).

224

225 Our study emphasizes the importance of these nnAb families in the immune response against HIV-

1, particularly in the presence of CD4mc, which "opens-up" the Env structure, exposing otherwise 226 hidden epitopes and thus facilitating a more effective immune attack on infected cells. This 227 228 approach holds promise for improving the immune system's ability to target and eliminate HIV-1-229 infected cells, potentially contributing to better control of HIV infection. The conserved nature of 230 these epitopes across different HIV-1 strains also suggests that this strategy could be applied cross-231 clade. Finally, our study suggests that a cocktail comprising monoclonal antibodies against these 232 epitopes, together with a CD4mc, could represent a potent strategy to eliminate HIV-1-infected 233 cells by ADCC.

234

235

236

#### 237 MATERIALS AND METHODS

#### 238

#### 239 Ethics statement

Written informed consent was obtained from all study participants and research adhered to the ethical guidelines of CRCHUM and was reviewed and approved by the CRCHUM institutional review board (ethics committee, approval number MP-02-2024-11734). Research adhered to the standards indicated by the Declaration of Helsinki. All participants were adult and provided informed written consent prior to enrollment in accordance with Institutional Review Board approval.

246

#### 247 Cell lines and primary cells

293T human embryonic kidney cells (obtained from ATCC) were maintained in Dulbecco's 248 Modified Eagle Medium (DMEM) (Wisent, St. Bruno, QC, Canada) supplemented with 5% fetal 249 250 bovine serum (FBS) (VWR, Radnor, PA, USA) and 100 U/mL penicillin/streptomycin (Wisent). 251 Human peripheral blood mononuclear cells (PBMCs) from five HIV-negative individuals (four 252 males and a female, age range 46-67 years) and four ART-treated HIV-positive individuals (all 253 males, age range 44-59 years) obtained by leukapheresis and Ficoll density gradient isolation were 254 cryopreserved in liquid nitrogen until further use. CD4+ T cells were purified from resting PBMCs 255 by negative selection using immunomagnetic beads per the manufacturer's instructions (StemCell Technologies, Vancouver, BC) and were activated with phytohemagglutinin-L (PHA-L, 10 µg/mL) 256 257 for 48h and then maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) 258 complete medium supplemented with 20% FBS, 100 U/mL penicillin/streptomycin and with 259 recombinant IL-2 (rIL-2, 100 U/mL). All cells were maintained at 37°C under 5% CO<sub>2</sub>.

260

#### 261 Human plasma samples

262 The FRQS-AIDS and Infectious Diseases Network supports a representative cohort of newly-HIVinfected subjects with clinical indication of primary infection [the Montreal Primary HIV Infection 263 Cohort (42, 43)]. Plasma samples were isolated from 50 PLWH and separated in five different 264 265 groups, depending on infection duration and treatment with ART: plasma samples were obtained 266 from never treated individuals during the acute phase of infection (0-100 days after infection), the early phase of infection (101-180 or 180-365 days after infection) or during the chronic phase of 267 infection (2-5 years after infection). Plasma samples were also obtained from a group of chronically 268 269 infected individuals (2-5 years after infection) under ART treatment. The demographic parameters

of the PLWH cohort is described in Table 1.

271

#### 272 Small CD4-mimetic

The small-molecule CD4-mimetic compound CJF-III-288 was synthesized as previously described (23). The compound was dissolved in DMSO at a stock concentration of 10 mM and then diluted to 50  $\mu$ M in PBS or in RPMI-1640 complete medium for cell-surface staining and for ADCC assays, respectively.

277

#### 278 Antibodies production and purification

279 FreeStyle 293F cells (Thermo Fisher Scientific) were grown in FreeStyle 293F medium (Thermo Fisher Scientific) to a density of  $1 \times 10^6$  cells/mL at 37°C with 8% CO<sub>2</sub> with regular agitation (150) 280 rpm). Cells were transfected with plasmids expressing the light and heavy chains of the anti-cluster 281 A A32, the anti-CoRBS 17b or the anti-gp41 cluster I F240 antibodies using ExpiFectamine 293 282 transfection reagent, as directed by the manufacturer (Thermo Fisher Scientific). One week later, 283 284 the cells were pelleted and discarded. The supernatants were filtered (0.22-µm-pore-size filter), and 285 antibodies were purified by protein A affinity columns, as directed by the manufacturer (Cytiva, 286 Marlborough, MA, USA). The recombinant protein preparations were dialyzed against phosphate-287 buffered saline (PBS) and stored in aliquots at -80°C. To assess purity, recombinant proteins were 288 loaded on SDS-PAGE polyacrylamide gels in the presence or absence of  $\beta$ -mercaptoethanol and 289 stained with Coomassie blue. 290 The A32, 17b and F240 Fab fragments were prepared from purified IgG (10 mg/mL) by proteolytic

291 digestion with immobilized papain (Pierce, Rockford, IL) and purified using protein A, followed

by gel filtration chromatography on a Superdex 200 16/60 column (Cytiva).

293

#### 294 Protein production and purification

295 ID2 was expressed and isolated as previously described (44). Briefly, stable HEK293 cell lines 296 containing the ID2 expression plasmid were cultured for 6-7 days before the collection of the 297 supernatant and passage through a 0.22 µm filter. Media were then run over an N5-i5 affinity 298 column, washed thoroughly with PBS and protein eluted with 0.1 M glycine at pH3. ID2 was 299 analyzed via SDS-PAGE, dialyzed to PBS and sterile filtered. For gp120 core  $\Delta V1V2V3V5$ 300 production, FreeStyle 293F cells (Invitrogen, Carlsbad, Ca, USA) were grown in FreeStyle 293F medium (Invitrogen) to a density of  $1 \times 10^6$  cells/ml at 37°C with 8% CO<sub>2</sub> with regular agitation 301 (125 rpm). Cells were transfected with a pCDNA3.1 plasmid encoding codon-optimized His(6)-302 tagged HIV-1<sub>YU2</sub> gp120 core ∆V1V2V3V5 using the ExpiFectamine<sup>™</sup> 293 Transfection Kit as 303 304 directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. The

supernatants were filtered (0.22-μm-pore-size filter) (ThermoFisher Waltham, MA, USA), and the
gp120 glycoproteins were purified by nickel affinity columns according to the manufacturer's
instructions (Invitrogen). Fractions containing gp120 were concentrated using Centriprep-30K
(EMDMillipore Billerica,MA, USA) centrifugal filter units following the manufacturer
instructions. Monomeric gp120 was then purified by FPLC as described (45). Monomeric gp120
preparations were dialyzed against PBS and stored in aliquots at -80°C. To assess purity,
recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie blue.

- 312 The gp41 peptide synthesis was previously described (40). The amino acid sequence of the 36-
- residue peptide of the sequence 583-618 of gp41 (based on the clade B BaL sequence) is gp41<sub>583-</sub>

314 618: VERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKS. The peptide was synthesized on 315 an ABI 433A automated peptide synthesizer using the optimized HBTU activation/DIEA in 316 situ neutralization protocol developed by Kent and colleagues for Boc-chemistry solid phase peptide synthesis (SPPS). After cleavage and deprotection in HF, crude product was precipitated 317 318 with cold ether and purified to homogeneity by preparative C18 reversed-phase HPLC to afford 319 reduced peptide. The molecular masses were confirmed by electrospray ionization mass 320 spectrometry (ESI-MS). Mass: observed 4082.0 Da, calculated 4081.6 Da. The reduced peptide 321 was dissolved at 0.4 mg/ml in 1 M GuHCl containing 20% DMSO (v/v) for disulfide formation. 322 After 2 hours, reaction was completed and purified with RP-HPLC to afford oxidized peptide. Mass

- 323 (ESI): observed. 4079.9 Da, calculated. 4079.6 Da.
- 324
- 325

#### 326 Antibodies

327 The anti-cluster A A32, the anti-CoRBS 17b or the anti-gp41 cluster I F240 antibodies were used 328 as controls in the different ELISA assays. The 17b Fab fragment was used to block anti-CoRBS 329 Abs binding in the anti-CoRBS ELISA assays. Horseradish peroxidase (HRP)-conjugated Ab 330 specific for the Fc region of human IgG (Invitrogen) was used as a secondary Ab to detect Ab 331 binding in ELISA experiments. Alexa Fluor-647-conjugated goat anti-human IgG (Thermo Fisher 332 Scientific) were used as secondary Ab to detect plasma binding in flow cytometry experiments. The A32, 17b and F240 Fab fragments were used to mask the cluster A, CoRBS and cluster I 333 334 epitopes, respectively, during flow cytometry cell-surface staining and ADCC assays. Anti-human IgG Fc secondary antibodies (Thermo Fisher Scientific) were used when cell surface binding was 335 336 performed in presence of Fab fragment blockade. The PE-conjugated anti-HIV p24 Ab (Clone 337 KC57-RD1, Beckman Coulter) and the FITC anti-human CD4 OKT4 Antibody (Biolegend) were

338 used to detect productively HIV-1 infected cells in flow cytometry cell-surface staining and ADCC

339 assays (27).

340

#### 341 Plasmids and proviral constructs

The infectious molecular clone (IMC) of HIV-1<sub>JRFL</sub> was kindly provided by Dr Dennis Burton (The
Scripps Research Institute). The vesicular stomatitis virus G (VSV-G)-encoding plasmid was
previously described (46).

345

#### **346** Viral production

347 VSV-G-pseudotyped HIV-1 viruses were produced by co-transfection of 293T cells with the HIV-348  $1_{JRFL}$  proviral construct and a VSV-G-encoding vector at a ratio of 3:2 using the polyethylenimine 349 (PEI) method. Two days post-transfection, cell supernatants were harvested, clarified by low-speed 350 centrifugation (300 × g for 5 min), and concentrated by ultracentrifugation at 4°C (100,605 × g for 351 1h) over a 20% sucrose cushion. Pellets were resuspended in fresh RPMI 1640 complete medium, 352 aliquoted and stored at -80°C until use.

353

#### 354 In vitro infections

VSV-G-pseudotyped HIV-1 viruses were used for *in vitro* infection. Briefly, primary CD4+ T cells from HIV-1 negative individuals were isolated from PBMCs, activated for 2 days with PHA-L and then maintained in RPMI 1640 complete medium supplemented with rIL-2. Five to seven days after activation, the cells were spinoculated with the HIV-1<sub>JRFL</sub> virus at 800 × g for 1h in 96-well plates at 25°C. All viral productions were titrated on primary CD4+ T cells to achieve similar levels of infection (around 12% of infected cells).

361

#### 362 Ex vivo expansion of HIV-infected CD4+ primary T cells

To expand endogenously infected CD4+ T cells, primary CD4+ T cells obtained from ART-treated PLWH were isolated from PBMCs by negative selection. CD4+ T cells were activated with PHA-L at 10 μg/mL for 48 h and then cultured for several days in RPMI 1640 complete medium supplemented with rIL-2 (100 U/mL). Intracellular anti-p24 staining was performed daily and an ADCC test was done when at least 7% of the cells were p24+.

368

#### 369 Flow cytometry analysis of cell-surface staining

370 Forty-eight hours after infection, HIV-1-infected primary CD4+ T cells were collected, washed

371 with PBS and transferred in 96-well V-bottom plates. The cells were then incubated for 45 min at

372 37°C with plasma (1:1000 dilution) in presence of CJF-III-288 (50 μM) or equivalent dilution of 373 DMSO. Cells were then washed twice with PBS and stained with anti-human IgG Alexa Fluor 647-374 conjugated secondary antibody (2 µg/mL), FITC-conjugated mouse anti-human CD4 (Clone OKT4) Antibody (1:500 dilution) and AquaVivid viability dye (Thermo Fisher Scientific, Cat# 375 376 L43957) for 20 min at room temperature. Alternatively, for blockade experiments, HIV-1-infected 377 cells were pre-incubated for 15 minutes at room temperature with DMSO/CJF-III-288 and 17b Fab 378 (20 µg/mL), A32 Fab (20 µg/mL) or F240 Fab (40 µg/mL) or the three Fab fragments together before addition of PLWH plasma. Alexa-Fluor-conjugated anti-human IgG Fc secondary 379 380 antibodies (1:1500 dilution) were used as secondary antibodies. Cells were then washed twice with 381 PBS and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized using the Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, Mississauga, ON, Canada) and 382 383 stained intracellularly using PE-conjugated mouse anti-p24 mAb (clone KC57; Beckman Coulter, Brea, CA, USA; 1:100 dilution). Samples were acquired on an Fortessa cytometer (BD 384 385 Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR, USA). The percentage of productively infected cells (p24<sup>+</sup>, CD4<sup>-</sup>) was determined by gating on the 386 living cell population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific). 387

388

#### 389 ADCC assay

390 ADCC activity was measured using a FACS-based infected cell elimination assay 48 hours after 391 infection. The HIV-1-infected primary CD4+ T cells were stained with AquaVivid viability dye 392 and cell proliferation dye eFluor670 (Thermo Fisher Scientific) and used as target cells. Resting 393 autologous PBMCs, were stained with cell proliferation dye eFluor450 (Thermo Fisher Scientific) 394 and used as effectors cells. The HIV-1-infected primary CD4+ T cells were co-cultured with 395 autologous PBMCs (Effector: Target ratio of 10:1) in 96-well V-bottom plates in the presence of 396 plasma from PLWH (dilution 1:1000) and CJF-III-288 (50 µM) or equivalent dilution of DMSO for 5h at 37°C. For blockade experiments, cells were pre-incubated for 15 minutes at room 397 398 temperature with DMSO/CJF-III-288 and 17b Fab (20 µg/mL), A32 Fab (20 µg/mL) or F240 Fab 399  $(40 \ \mu g/mL)$  or the three Fabs before addition of plasma and effector cells. After the 5h incubation, 400 cells were then washed once with PBS and stained with FITC-conjugated mouse anti-human CD4 401 (Clone OKT4) antibody for 20 min at room temperature. Cells were then washed twice with PBS and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized and stained 402 intracellularly for p24 as described above. Samples were acquired on a Fortessa cytometer (BD 403 404 Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR, 405 USA). The percentage of infected cells  $(p24^+, CD4^-)$  was determined by gating on the living cell

406 population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific). The 407 percentage of ADCC was calculated with the following formula:  $[(\% \text{ of } p24^+CD4^- \text{ cells in Targets}$ 408 plus Effectors) – (% of p24<sup>+</sup>CD4<sup>-</sup> cells in Targets plus Effectors plus plasma)/(% of p24<sup>+</sup>CD4<sup>-</sup> cells

- 409 in Targets)  $\times$  100].
- 410

#### 411 Anti-cluster A ELISA assay

412 Recombinant stabilized gp120 inner domain (ID2) exposing the A32 epitope was previously described (33, 44). The recombinant proteins were prepared in PBS at a concentration of 0.1  $\mu$ g/mL 413 414 and were adsorbed to white 96-well plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were 415 subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween 20 and 2% bovin serum albumin (BSA)) for 1h at room temperature. Wells were then washed four 416 417 times with washing buffer (TBS containing 0.1% Tween 20). Plasma samples (dilution 1:8000), two-fold serial dilution of anti-cluster A A32 Ab (from 50 to 0.4 ng/mL) to determine concentration 418 419 using a standard curve, and another dilution of A32 at 1  $\mu$ g/mL for normalization between plates 420 was prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the peptide-421 coated wells for 90 min at room temperature. Plates were washed four times with washing buffer 422 followed by incubation with HRP-conjugated anti-human IgG secondary Ab (0.3 µg/mL in a 423 diluted solution of blocking buffer [0.4% BSA]) for 1h at room temperature, followed by four 424 washes. HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning 425 Plus-ECL oxidizing and luminol reagents (PerkinElmer Life Sciences). Light emission was 426 measured with an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with BSA 427 was subtracted for each plasma and normalized to the signal obtained with A32 present in each plate. Concentration of the plasma was determined with the A32 standard curve. The seropositivity 428 429 threshold was established using the following formula: mean of 8 plasma from HIV-1-uninfected 430 individuals + (3 standard deviation of the mean of 8 HIV negative plasma).

431

#### 432

#### 433 Anti-CoRBS ELISA

Recombinant CD4 bound stabilized gp120 proteins, lacking V1, V2, V3 and V5 regions (gp120 core  $\Delta$ V1V2V3V5 was previously described (25, 33). Proteins were prepared in PBS at a concentration of 0.1 µg/mL and were adsorbed to white 96-well plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween 20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with washing buffer (TBS containing 0.1% Tween 20). Anti-CoRBS 17b Fab fragment (0.5 µg/mL)

440 were prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the half of 441 the peptide-coated wells for 90 min at room temperature. The other half of the plate was incubated 442 with a solution of blocking buffer (0.1% BSA). Wells were then washed four times with washing buffer (TBS containing 0.1% Tween 20). Plasma samples (dilution 1:8000), two-fold serial dilution 443 444 of anti-CoRBS 17b Ab (from 50 to 0.4 ng/mL) to determine concentration using a standard curve, 445 and another dilution of 17b at 1  $\mu$ g/mL for normalization between plates was prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the peptide-coated wells for 90 min at 446 447 room temperature. Plates were washed four times with washing buffer followed by incubation with 448 HRP-conjugated anti-human IgG secondary Ab (0.3 µg/mL in a diluted solution of blocking buffer 449 [0.4% BSA]) for 1h at room temperature, followed by four washes. HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning Plus-ECL oxidizing and luminol 450 451 reagents (PerkinElmer Life Sciences). Light emission was measured with an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with BSA was subtracted for each plasma 452 453 and was then normalized to the signal obtained with 17b present in each plate. Concentration of the 454 plasma was determined with the 17b standard curve. The anti-CoRBS antibody level corresponds to the value obtained when the concentration obtained with 17b Fab preincubation condition is 455 456 subtracted from that without 17b Fab preincubation condition. The seropositivity threshold was 457 established using the following formula: mean of 8 plasmas from HIV-1-uninfected individuals + 458 (3 standard deviation of the mean of 8 HIV negative plasma).

459

#### 460 Anti-gp41 cluster I peptide ELISA

461 Peptides corresponding to the gp41 C-C loop region (residues 583–618) were either previously described (16, 40) or purchased from Genscript (Piscataway, NJ, USA). Peptides were prepared in 462 463 PBS at a concentration of 0.1 µg/mL and were adsorbed to white 96-well plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered 464 465 saline [TBS] containing 0.1% Tween 20 and 2% BSA) for 1 h at room temperature. Wells were 466 then washed four times with washing buffer (TBS containing 0.1% Tween 20). Plasma samples 467 (dilution 1:8000), two-fold serial dilution of anti-gp41 cluster I F240 Ab (from 50 to 0.4 ng/mL) to determine concentration using a standard curve, and another dilution of F240 at 1 µg/mL for 468 469 normalization between plates was prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the peptide-coated wells for 90 min at room temperature. Plates were washed 470 four times with washing buffer followed by incubation with HRP-conjugated anti-human IgG 471 472 secondary Ab (0.3 µg/mL in a diluted solution of blocking buffer [0.4% BSA]) for 1h at room 473 temperature, followed by four washes. HRP enzyme activity was determined after the addition of

a 1:1 mix of Western Lightning Plus-ECL oxidizing and luminol reagents (PerkinElmer Life
Sciences). Light emission was measured with an LB942 TriStar luminometer (Berthold
Technologies). Signal obtained with BSA was subtracted for each plasma and was then normalized
to the signal obtained with F240 present in each plate. Concentration of the plasma was determined
with the F240 standard curve. The seropositivity threshold was established using the following
formula: mean of 8 plasmas from HIV-1-uninfected individuals + (3 standard deviation of the mean
of 8 HIV negative plasma).

481

#### 482 Sequences analysis

483 The LOGO plot was created using the Analyze Align tool at the Los Alamos National Laboratory 484 HIV database which is based on the WebLogo program 485 (https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze align.html) and the HIV-1 database global curated and filtered 2019 alignment, including 6,223 individual Env protein 486 487 sequences (47). The relative height of each letter within individual stack represents the frequency 488 of the indicated amino acid at that position. The numbering of Env amino acid sequences is based on the HXB2 reference strain of HIV-1, where 1 is the initial methionine. 489

490

#### 491 QUANTIFICATION AND STATISTICAL ANALYSIS

492 Statistics were analyzed using GraphPad Prism version 10.2.0 (GraphPad, San Diego, CA, USA). 493 Every data set was tested for statistical normality and this information was used to apply the 494 appropriate (parametric or nonparametric) statistical test. Statistical details of experiments are 495 indicated in the figure legends. p values < 0.05 were considered significant; significance values are 496 indicated as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

497

#### 498 ACKNOWLEDGMENTS

499 The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance, 500 Mario Legault from the FRQS AIDS and Infectious Diseases network for cohort coordination and clinical samples. This study was supported by grants from the National Institutes of Health to A.F. 501 502 (R01 AI148379, R01 AI150322, AI176531); A.F. and M.P., (R01 AI129769, AI174908). Support 503 for this work was also provided by the NIAID-funded ERASE HIV consortium (UM1 AI-164562) to A.B.S. and A.F., by a CIHR Team Grant #422148, a project grant #451304 and a Canada 504 Foundation for Innovation grant #41027 to A.F. A.F. was supported by a Canada Research Chair 505 506 on Retroviral Entry #RCHS0235 950-232424. M.B. and G.B-B. are the recipients of CIHR doctoral 507 fellowship. E.B. is a recipient of a CIHR master fellowships. J.P. was the recipients of a CIHR

508 doctoral fellowship. A.T. was supported by a MITACs Elevation post-doctoral fellowship. The

- 509 funders had no role in study design, data collection and analysis, decision to publish, or preparation
- 510 of the manuscript.
- 511

#### 512 DISCLAIMER

- 513 The views expressed in this manuscript are those of the authors and do not reflect the official policy
- or position of the Uniformed Services University, the U.S. Army, the Department of Defense, the
- 515 National Institutes of Health, Department of Health and Human Services or the U.S. Government,
- 516 nor does it mention of trade names, commercial products, or organizations imply endorsement by
- 517 the U.S. Government.

518 Figure legends

519

520 Figure 1. CJF-III-288 enhances recognition and ADCC-mediated elimination of HIV+ infected cells by PLWH plasma. (A, D) HIV+ infected CD4+ T cells recognition by 50 PLWH 521 522 plasma in presence of CJF-III-288 (50  $\mu$ M) or equivalent volume of DMSO. The panel A shows 523 the results obtained with the plasma from the 50 PLWH, and the panel **D** shows the results 524 depending on infection duration and treatment with antiretroviral therapy. (B, E) PLWH plasma-525 mediated ADCC in presence of CJF-III-288 (50  $\mu$ M) or equivalent volume of DMSO. The panel **B** 526 shows the results obtained with plasma from the 50 PLWH, and the panel E shows the results 527 depending on infection duration and treatment with antiretroviral therapy of the individuals. (C) Spearman correlation between the capacity of the plasma to recognize the infected cells and to 528 529 mediate ADCC in presence of DMSO (grey), CJF-III-288 (blue) or both conditions (black). Error bars indicate means  $\pm$  SEM (\*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001). The data shows the mean 530 of 3 independent experiments. Statistical significance was tested using paired t tests or Wilcoxon 531 532 matched-pairs signed rank test, based on statistical normality.

533

534 Figure 2. Correlations between the level of three families of non-neutralizing antibodies and 535 plasma binding and ADCC activity. (A-B) Indirect ELISA was performed by incubating plasma 536 samples from 50 PLWH to measure the levels of antibodies recognizing specifically the CoRBS, 537 the cluster A or the gp41 cluster I epitopes (see materials and methods section for more details). CD4i Abs was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values 538 539 obtained with BSA (negative control) were subtracted and further normalized to the signal obtained 540 with the appropriate control mAb (17b for the CoRBS, A32 for the cluster A and F240 for the gp41 541 cluster I ELISA) present in each plate. The panel A shows the results obtained with the plasma from the 50 PLWH, and the panel **B** shows the results depending on infection duration and 542 treatment with antiretroviral therapy of the individuals. (C-E) Spearman correlations between the 543 544 capacity of plasma samples from 50 PLWH to recognize the infected cells in presence of DMSO (gray) or CJF-III-288 at 50 µM (blue) and the level of anti-CoRBS (C), anti-cluster A (D) or anti-545 546 gp41 cluster I (E) antibodies present in these plasmas. (F-H) Spearman or Pearson correlations between the capacity of plasma samples to mediated ADCC in presence of DMSO (gray) or CJF-547 548 III-288 at 50  $\mu$ M (blue) and the level of anti-CoRBS (F), anti-cluster A (G) or anti-gp41 cluster I 549 (H) antibodies present in these plasmas. The data shows the mean of 3 independent experiments. 550 Error bars indicate means  $\pm$  SEM (\*p < 0.05; \*\*p < 0.01; \*\*\*\*p < 0.0001; ns, non-significant).

551 Statistical significance was tested using paired t tests or Wilcoxon matched-pairs signed rank test,

- 552 based on statistical normality.
- 553

#### Figure 3. Anti-CoRBS, anti-cluster A and anti-gp41 cluster I CD4-induced Abs contribute to 554 ADCC mediated by plasma from PLWH in presence of a CD4mc. (A) HIV+ infected CD4+ T 555 556 cells recognition and (B) ADCC activity of plasma from 20 PLWH (from the two groups of donors, 557 untreated or ART-treated, collected 2-5 years after infection) in presence of DMSO or CJF-III-288 558 (50 µM, blue) with or without pre-incubation with anti-cluster A A32 Fab, or anti-gp41 cluster I F240 Fab or anti-CoRBS 17b Fab or the three Fab fragments. Error bars indicate means ± SEM (\*p 559 < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; ns, non-significant). Statistical significance was 560 561 tested using paired t tests, based on statistical normality.

562

563 Figure 4. ADCC activity of PLWH plasma against autologous ex vivo expanded CD4+ T cells 564 in presence of CJF-III-288. (A) HIV+ infected CD4+ T cells isolated from PLWH were expanded 565 ex vivo. (B) HIV-1-infected cells recognition at the surface of infected cells by autologous plasma 566 in presence of DMSO (grey), CJF-III-288 (blue) or CJF-III-288 with or without preincubation with 567 the three Fab fragments (red). The graph shows the results obtained for a representative donor. (C) 568 ADCC activity in presence of DMSO (gray) or CJF-III-288 (50 µM, blue) with autologous plasma 569 after or not pre-incubation with anti-cluster A A32 Fab, anti-gp41 cluster I F240 Fab and anti-570 CoRBS 17b Fab fragments. Each symbol represent data from an individual donor.

571

572 Figure 5. Anti-cluster A, anti-CoRBS and anti-gp41 cluster I Abs recognized highly conserved 573 epitopes in the Env. Env residues forming epitopes for cluster A, CoRBS and gp41 cluster I region are highlighted in pink, yellow and cyan, respectively. Epitope residues are defined as gp120 574 (cluster A and CoRBS) or gp41 (cluster I) residues contributing buried surface area to the Fab-Env 575 576 antigen interface as calculated by PISA (http://www.ebi.ac.uk/msd-srv/prot int/cgi-bin/piserver). 577 Calculations were done based on available Env antigen complexes of cluster A Abs: A32 (PDB code: 4YC2 and 4YBL), N5-i5 (PDB code: 4H8W), 2.2c (PDB code: 4R4F), N60-i3 (PDB code: 578 579 4RFO), JR4 (PDB code: 4RFN), CH54 (PDB code: 6MG7), CH55 (PDB code: 6OFI), DH677.3 580 (PDB code: 6MFP), C11 (PDB code: 6OEJ), and N12-i3 (PDB code: 5W4L); CoRBS Abs: 17b 581 (PDB code: 1GC1), 48d (PDB code: 4DVR), N12-i2 (PDB code: 6W4M), 412d (PDB code: 582 2QAD), X5 (PDB code: 2B4C); and cluster I Abs: F240 (PDB code: 7N05) and 7B2 (PDB code: 583 4YDV) Cluster I region includes also 246D epitope residues defined based on peptide mapping as 584 in PMID: 1714520.

#### 585 **REFERENCES**

586

596

- Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C,
   Haseltine W, Sodroski J. 1987. Functional regions of the envelope glycoprotein of human
- immunodeficiency virus type 1. Science 237:1351–1355.
- Freed EO, Martin MA. 1995. The role of human immunodeficiency virus type 1 envelope
   glycoproteins in virus infection. J Biol Chem 270:23883–23886.
- 592 3. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB,

593 Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1

- envelope trimers on the surface of native virions. Science 346:759–763.
- 4. Ma X, Lu M, Gorman J, Terry DS, Hong X, Zhou Z, Zhao H, Altman RB, Arthos J, Blanchard

SC, Kwong PD, Munro JB, Mothes W. 2018. HIV-1 Env trimer opens through an asymmetric

- 597 intermediate in which individual protomers adopt distinct conformations. eLife 7:e34271.
- 598 5. Li W, Qin Z, Nand E, Grunst MW, Grover JR, Bess JW, Lifson JD, Zwick MB, Tagare HD,
- 599 Uchil PD, Mothes W. 2023. HIV-1 Env trimers asymmetrically engage CD4 receptors in
  600 membranes. Nature 623:1026–1033.
- 601 6. Lu M, Ma X, Castillo-Menendez LR, Gorman J, Alsahafi N, Ermel U, Terry DS, Chambers
- 602 M, Peng D, Zhang B, Zhou T, Reichard N, Wang K, Grover JR, Carman BP, Gardner MR,
- 603 Nikic-Spiegel I, Sugawara A, Arthos J, Lemke EA, Smith AB, Farzan M, Abrams C, Munro
- JB, McDermott AB, Finzi A, Kwong PD, Blanchard SC, Sodroski JG, Mothes W. 2019.
- Associating HIV-1 envelope glycoprotein structures with states on the virus observed by
   smFRET. Nature 568:415–419.
- 607 7. Chen B. 2019. Molecular Mechanism of HIV-1 Entry. Trends Microbiol 27:878–891.

608	8.	Shaik MM, Peng H, Lu J, Rits-Volloch S, Xu C, Liao M, Chen B. 2019. Structural basis of
609		coreceptor recognition by HIV-1 envelope spike. Nature 565:318-323.

- 610 9. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. 1994. Nef induces CD4 endocytosis:
- 611 requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
- 612 Cell 76:853–864.
- 613 10. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1
  614 Vpu protein induces rapid degradation of CD4. J Virol 66:7193–7200.
- 615 11. Veillette M, Désormeaux A, Medjahed H, Gharsallah N-E, Coutu M, Baalwa J, Guan Y, Lewis
- 616 G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J,
- Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by
  antibody-dependent cell-mediated cytotoxicity. J Virol 88:2633–2644.
- Veillette M, Coutu M, Richard J, Batraville L-A, Dagher O, Bernard N, Tremblay C,
  Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-bound conformation is
  preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in
  sera from HIV-1-infected individuals. J Virol 89:545–551.
- Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schön A, Freire
  E, Routy J-P, Smith AB, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH,
- 625 Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV-
- 626 1-infected cells to ADCC. Proc Natl Acad Sci U S A 112:E2687-2694.
- 14. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prévost J,
  Chapleau J-P, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B, Martin L, Tremblay
  C, Hahn BH, Kaufmann DE, Wu X, Smith AB, Sodroski J, Pazgier M, Finzi A. 2016. Co-

630	receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A
631	ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine 12:208–218.

- 15. Laumaea A, Marchitto L, Ding S, Beaudoin-Bussières G, Prévost J, Gasser R, Chatterjee D,
- 633 Gendron-Lepage G, Medjahed H, Chen H-C, Smith AB, Ding H, Kappes JC, Hahn BH,
- 634 Kirchhoff F, Richard J, Duerr R, Finzi A. 2023. Small CD4 mimetics sensitize HIV-1-infected
- 635 macrophages to antibody-dependent cellular cytotoxicity. Cell Rep 42:111983.
- 636 16. Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-
- 637 Lepage G, Chen H-C, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton
- 638 DR, Flavell RA, Kirchhoff F, Hahn BH, Smith AB, Pazgier M, Nussenzweig MC, Kumar P,
- 639 Finzi A. 2022. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Rep640 41:111624.
- 17. Alsahafi N, Bakouche N, Kazemi M, Richard J, Ding S, Bhattacharyya S, Das D, Anand SP,
- 642 Prévost J, Tolbert WD, Lu H, Medjahed H, Gendron-Lepage G, Ortega Delgado GG, Kirk S,
- 643 Melillo B, Mothes W, Sodroski J, Smith AB, Kaufmann DE, Wu X, Pazgier M, Rouiller I,
- 644 Finzi A, Munro JB. 2019. An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-
- 645 Dependent Cellular Cytotoxicity. Cell Host Microbe 25:578-587.e5.
- 18. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure
  of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing
  human antibody. Nature 393:648–659.
- 649 19. Melillo B, Liang S, Park J, Schön A, Courter JR, LaLonde JM, Wendler DJ, Princiotto AM,
- 650 Seaman MS, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB. 2016. Small-
- 651 Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Med
- 652 Chem Lett 7:330–334.

653	20. Madani N, Schön A, Princiotto AM, LaLonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower
654	ET, Xiang S-H, Kwon YD, Huang C, Wyatt R, Kwong PD, Freire E, Smith AB, Sodroski J.
655	2008. Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120.
656	Struct Lond Engl 1993 16:1689–1701.

- 657 21. Prévost J, Tolbert WD, Medjahed H, Sherburn RT, Madani N, Zoubchenok D, Gendron-
- 658 Lepage G, Gaffney AE, Grenier MC, Kirk S, Vergara N, Han C, Mann BT, Chénine AL,
- Ahmed A, Chaiken I, Kirchhoff F, Hahn BH, Haim H, Abrams CF, Smith AB, Sodroski J,
- 660 Pazgier M, Finzi A. 2020. The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and
- the CD4 Binding Site. mBio 11:e00280-20.
- Anang S, Zhang S, Fritschi C, Chiu T-J, Yang D, Smith III AB, Madani N, Sodroski J. V3 tip
  determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A
  human immunodeficiency virus (HIV-1) envelope glycoproteins. J Virol 97:e01171-23.
- 665 23. Fritschi CJ, Anang S, Gong Z, Mohammadi M, Richard J, Bourassa C, Severino KT, Richter
  666 H, Yang D, Chen H-C, Chiu T-J, Seaman MS, Madani N, Abrams C, Finzi A, Hendrickson
  667 WA, Sodroski JG, Smith AB. Indoline CD4-mimetic compounds mediate potent and broad
  668 HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. Proc Natl Acad
  669 Sci U S A 120:e2222073120.
- Anand SP, Prévost J, Baril S, Richard J, Medjahed H, Chapleau J-P, Tolbert WD, Kirk S, Smith
  AB, Wines BD, Kent SJ, Hogarth PM, Parsons MS, Pazgier M, Finzi A. 2019. Two Families
  of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected
  Cells. J Virol 93:e01823-18.
- 25. Rajashekar JK, Richard J, Beloor J, Prévost J, Anand SP, Beaudoin-Bussières G, Shan L,
  Herndler-Brandstetter D, Gendron-Lepage G, Medjahed H, Bourassa C, Gaudette F, Ullah I,

01

6/6	Symmes K, Peric A, Lindemuth E, Bibollet-Ruche F, Park J, Chen H-C, Kauimann DE, Hann
677	BH, Sodroski J, Pazgier M, Flavell RA, Smith AB, Finzi A, Kumar P. 2021. Modulating HIV-
678	1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host Microbe
679	29:904-916.e6.

- 680 26. Beaudoin-Bussières G, Prévost J, Gendron-Lepage G, Melillo B, Chen J, Smith III AB, Pazgier
- 681 M, Finzi A. 2020. Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are
- 682 Required to Eliminate HIV-1 Infected Cells. 5. Microorganisms 8:710.

~ - ~

- 683 27. Richard J, Sannier G, Zhu L, Prévost J, Marchitto L, Benlarbi M, Beaudoin-Bussières G, Sun
- 684 Y, Hongil K, Chatterjee D, Medjahed H, Bourassa C, Delgado G-G, Dubé M, Kirchhoff F,
- Hahn BH, Kumar P, Kaufmann DE, Finzi A. 2024. CD4 downregulation precedes Env
- expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing
  antibodies. bioRxiv https://doi.org/10.1101/2024.05.01.592003.
- 28. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 Envelope Glycoprotein Biosynthesis,
  Trafficking, and Incorporation. J Mol Biol 410:582–608.
- 690 29. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M,
- 691 Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE,
- 692 Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding
  693 site. J Exp Med 201:1407–1419.
- 30. Tolbert WD, Sherburn RT, Van V, Pazgier M. 2019. Structural Basis for Epitopes in the gp120
  Cluster A Region that Invokes Potent Effector Cell Activity. Viruses 11:69.
- Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X,
  Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK. 2013. Diverse

698	specificity and effector function among human antibodies to HIV-1 envelope glycoprotein
699	epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 110:E69-78.
700	32. Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang C-C, Kwon YD,
701	Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS,

- 702 Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis
- 703 GK, Pazgier M. 2014. Structural definition of an antibody-dependent cellular cytotoxicity
- response implicated in reduced risk for HIV-1 infection. J Virol 88:12895–12906.
- 33. Tolbert WD, Gohain N, Veillette M, Chapleau J-P, Orlandi C, Visciano ML, Ebadi M, DeVico
- AL, Fouts TR, Finzi A, Lewis GK, Pazgier M. 2016. Paring Down HIV Env: Design and
- 707 Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC
- Target of the A32 Region. Struct England1993 24:697–709.
- Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. 1991. Epitope mapping of two
  immunodominant domains of gp41, the transmembrane protein of human immunodeficiency
  virus type 1, using ten human monoclonal antibodies. J Virol 65:4832–4838.
- 712 35. Vézina D, Gong SY, Tolbert WD, Ding S, Nguyen D, Richard J, Gendron-Lepage G, Melillo
- B, Smith AB, Pazgier M, Finzi A. 2021. Stabilizing the HIV-1 envelope glycoprotein State 2A
  conformation. J Virol 95:e01620-20, JVI.01620-20.
- 715 36. Finzi A, Xiang S-H, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD,
- Sodroski J. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41
  interaction and CD4-triggered conformational transitions. Mol Cell 37:656–667.
- 718 37. Ding S, Tolbert WD, Prévost J, Pacheco B, Coutu M, Debbeche O, Xiang S-H, Pazgier M,
- Finzi A. 2016. A Highly Conserved gp120 Inner Domain Residue Modulates Env
  Conformation and Trimer Stability. J Virol 90:8395–8409.

721	38. Rasheed M, Bettadapura R, Bajaj C. 2015. Computational Refinement and Validation Protocol
722	for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b
723	Bound State, Struct Lond Engl 1993 23:1138–1149

- 39. Huang C, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang M-Y, Dimitrov DS, Hendrickson
- 725 WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. 2004. Structural basis
- of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1
- coreceptor-binding site on gp120. Proc Natl Acad Sci U S A 101:2706–2711.
- 40. Gohain N, Tolbert WD, Orlandi C, Richard J, Ding S, Chen X, Bonsor DA, Sundberg EJ, Lu
- W, Ray K, Finzi A, Lewis GK, Pazgier M. 2016. Molecular basis for epitope recognition by
- non-neutralizing anti-gp41 antibody F240. Sci Rep 6:36685.
- 41. Cook JD, Khondker A, Lee JE. 2022. Conformational plasticity of the HIV-1 gp41
  immunodominant region is recognized by multiple non-neutralizing antibodies. Commun Biol
  5:291.
- 42. Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M, Montreal Primary HIV
  Infection and Long-Term Non-Progressor Study Groups. 2011. High expression levels of B
  lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease
  progression in humans. Blood 117:145–155.
- 43. Fontaine J, Coutlée F, Tremblay C, Routy J-P, Poudrier J, Roger M, Montreal Primary HIV
  Infection and Long-Term Nonprogressor Study Groups. 2009. HIV infection affects blood
  myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J
  Infect Dis 199:1007–1018.
- 44. Visciano ML, Gohain N, Sherburn R, Orlandi C, Flinko R, Dashti A, Lewis GK, Tolbert WD,
  Pazgier M. 2019. Induction of Fc-Mediated Effector Functions Against a Stabilized Inner

- Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region. Front
- 745 Immunol 10:677.
- 45. Coutu M, Finzi A. 2015. HIV-1 gp120 dimers decrease the overall affinity of gp120
- 747 preparations for CD4-induced ligands. J Virol Methods 215–216:37–44.
- 46. Emi N, Friedmann T, Yee JK. 1991. Pseudotype formation of murine leukemia virus with the
- G protein of vesicular stomatitis virus. J Virol 65:1202–1207.
- 47. Crooks GE, Hon G, Chandonia J-M, Brenner SE. 2004. WebLogo: a sequence logo generator.
- 751 Genome Res 14:1188–1190.

752

Group	Ser Female (n)	x Male (n)	Age (years)	Days since infection	Days between infection and ART initiation	Days since ART initiation	Viral load (copies/mL)	CD4 count (cells/mm <sup>3</sup> )
0-100 days	0	10	41 (18-55)	68 (42-97)	N/A N/A		60848 (132-391113)	470 (330-829)
101-180 days	0	10	38 (19-58)	138 (109-177)	N/A	N/A N/A		650 (420-1235)
181-365 days	0	10	31 (24-44)	240 (203-314)	N/A	N/A	22785 (1866-260852)	490 (230-770)
2-5 years	1	11	34 (20-51)	1158 (856-1810)	N/A	N/A	292340 (14255- 809600)	410 (200-1050)
2-5 years	1	7	34 (21-58)	1012 (792-1612)	744 (19-1375)	386 (192-986)	50 (40-3337)	585 (170-1149)


Table 1: Characteristics of the cohort of people living with HIV, related to Figures 1, 2 and 3.

\*Values displayed are medians, with ranges in parentheses.

# Table 2: Demographic characterization of PLWH used to expand primary infected CD4+ T cells, related to Figure 4.


Donors	Age	Sex	Time since infection (years)	Time since ART initiation (years)	Plasma viral load
1-4	56 (44-59)	All males	23 (14-34)	7.5 (2-13)	All undetectables

\*Values displayed are medians, with ranges in parentheses.





Plasma binding (MFI)


D





Ε












Α



Β

